CN109069420A - 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法 - Google Patents

2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法 Download PDF

Info

Publication number
CN109069420A
CN109069420A CN201780016491.0A CN201780016491A CN109069420A CN 109069420 A CN109069420 A CN 109069420A CN 201780016491 A CN201780016491 A CN 201780016491A CN 109069420 A CN109069420 A CN 109069420A
Authority
CN
China
Prior art keywords
abdnaz
preparation
cancer
patient
whole blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780016491.0A
Other languages
English (en)
Chinese (zh)
Inventor
布莱恩·T·奥兰斯基
简·塞森斯基
斯科特·卡罗恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epicentrx Inc
Original Assignee
Epicentrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicentrx Inc filed Critical Epicentrx Inc
Priority to CN202410255228.9A priority Critical patent/CN118236371A/zh
Publication of CN109069420A publication Critical patent/CN109069420A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201780016491.0A 2016-01-11 2017-01-11 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法 Pending CN109069420A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410255228.9A CN118236371A (zh) 2016-01-11 2017-01-11 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277236P 2016-01-11 2016-01-11
US62/277,236 2016-01-11
PCT/US2017/012948 WO2017123593A1 (en) 2016-01-11 2017-01-11 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410255228.9A Division CN118236371A (zh) 2016-01-11 2017-01-11 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法

Publications (1)

Publication Number Publication Date
CN109069420A true CN109069420A (zh) 2018-12-21

Family

ID=59311661

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780016491.0A Pending CN109069420A (zh) 2016-01-11 2017-01-11 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法
CN202410255228.9A Pending CN118236371A (zh) 2016-01-11 2017-01-11 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410255228.9A Pending CN118236371A (zh) 2016-01-11 2017-01-11 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法

Country Status (15)

Country Link
US (3) US11576895B2 (https=)
EP (1) EP3402480B1 (https=)
JP (1) JP6931004B2 (https=)
KR (1) KR20190040931A (https=)
CN (2) CN109069420A (https=)
AU (1) AU2017207304B2 (https=)
CA (1) CA3011103A1 (https=)
DK (1) DK3402480T3 (https=)
EA (1) EA201891606A1 (https=)
ES (1) ES2880482T3 (https=)
IL (1) IL260515B1 (https=)
MX (1) MX2018008528A (https=)
PL (1) PL3402480T3 (https=)
SG (1) SG11201805942UA (https=)
WO (1) WO2017123593A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
CN109069420A (zh) 2016-01-11 2018-12-21 埃皮辛特瑞柯斯公司 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法
CN110352190A (zh) 2016-10-14 2019-10-18 埃皮辛特瑞柯斯公司 用于医疗用途的磺氧基烷基有机硝基和相关化合物和药物组合物
US11744859B2 (en) 2017-07-07 2023-09-05 Epicentrx, Inc. Compositions and methods for parenteral administration of therapeutic agents
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
WO2019241276A1 (en) 2018-06-11 2019-12-19 Epicentrx, Inc. Medication infusion devices, systems, and methods
CN115243741A (zh) 2019-12-11 2022-10-25 埃皮辛特瑞柯斯公司 药物输注装置、系统和方法
IL309043A (en) * 2021-06-09 2024-02-01 Epicentrx Inc Crystalline Abdenase compositions and methods for their preparation and use
US20250134858A1 (en) * 2022-02-10 2025-05-01 Epicentrx, Inc. Compositions and methods for treatment of nafld and nash and related dyslipidemias
WO2024098009A1 (en) 2022-11-04 2024-05-10 Epicentrx, Inc. Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications
WO2024124152A1 (en) 2022-12-08 2024-06-13 Epicentrx, Inc. Rrx-001 for the treatment of a hemoglobinopathy
WO2024145484A1 (en) * 2022-12-29 2024-07-04 Epicentrx, Inc. Rrx-001 for treating reproductive-related disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370492A (zh) * 2005-08-12 2009-02-18 阿利安特技术系统股份有限公司 环状硝基化合物及其药物组合物和用途
WO2012078992A1 (en) * 2010-12-09 2012-06-14 Radiorx, Inc. Organonitro compounds for use in treating non-hodgkin's lymphoma and leukemia, and methods relating thereto
WO2013052803A2 (en) * 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
WO2013052164A1 (en) * 2011-10-07 2013-04-11 Radiorx, Inc. Organonitro thioether compounds and medical uses thereof

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2978453A (en) 1956-12-12 1961-04-04 Aerojet General Co 3, 3, 5, 5-tetranitropiperidine
JPS4830376B1 (https=) 1970-12-29 1973-09-19
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5511509A (en) 1978-07-07 1980-01-26 Toomasu Gorudon Robaato Cancer therapy
US4935450A (en) 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
GB8728418D0 (en) 1987-12-04 1988-01-13 Jenkins T C Nitro-substituted aromatic/hetero-aromatic compounds for use in cancer treatment
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5693794A (en) 1988-09-30 1997-12-02 The United States Of America As Represented By The Secretary Of The Navy Caged polynitramine compound
JP2659614B2 (ja) 1990-11-13 1997-09-30 株式会社日立製作所 表示制御装置
TW198712B (https=) 1991-04-17 1993-01-21 Hoffmann La Roche
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP0611306B1 (en) 1991-11-08 1998-07-08 Somatogen, Inc. Hemoglobins as drug delivery agents
DE4226974C2 (de) 1992-08-14 1994-08-11 Fresenius Ag Verfahren und Vorrichtung zur kontinuierlichen Aufbereitung einer Zellsuspension
US5336784A (en) 1993-06-07 1994-08-09 The Regents Of The University Of California Synthesis of 1,3,3-trinitroazetidine
JP3211892B2 (ja) 1994-05-27 2001-09-25 セイジィ ファーマスーティカルス インコーポレーテッド 肛門疾患を治療する窒素酸化物供与体及び方法
EE9700138A (et) 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
EP0814860B1 (en) 1995-03-14 1999-11-03 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosating unit
US5970974A (en) 1995-03-14 1999-10-26 Siemens Aktiengesellschaft Dosating unit for an ultrasonic atomizer device
AU5798996A (en) 1995-05-15 1996-11-29 Sachs, Michael C. Adnaz, compositions and processes
US5580988A (en) 1995-05-15 1996-12-03 The United States Of America As Represented By The Secretary Of The Army Substituted azetidines and processes of using them
US5898038A (en) 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
AU738341B2 (en) 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
IL128589A0 (en) 1996-10-15 2000-01-31 Eastman Chem Co Explosive formulations
US5945446A (en) 1997-02-10 1999-08-31 Laubc Biochemicals, Corporation Process for preparing synthetic soil-extract materials and medicaments based thereon
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9720797D0 (en) 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
US6056966A (en) 1998-05-18 2000-05-02 Baker Norton Pharmaceuticals, Inc. Method and compositions for treating impotence
CA2337690C (en) 1998-07-27 2013-10-01 Texas Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6391911B1 (en) 1999-02-26 2002-05-21 Robert E. Bases Coadministration of lucanthone and radiation for treatment of cancer
US20020077276A1 (en) 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
HUP0300413A2 (hu) 2000-04-10 2003-06-28 Pfizer Products Inc. Amidcsoportot viselő benzolgyűrűs csoporttal helyettesített piperidint tartalmazó és rokonszerkezetű vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US6861530B2 (en) 2000-07-07 2005-03-01 Kyowa Hakko Kogyo Co., Ltd. Piperidine derivatives
RU2188026C1 (ru) 2001-01-12 2002-08-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака почки
DE10111049A1 (de) 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
WO2003057129A1 (en) 2001-12-28 2003-07-17 Terumo Kabushiki Kaisha Blood bag system and method of inactivating pathogenic microorganisms
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
AU2003247792B2 (en) 2002-07-03 2009-09-24 Nicox S.A. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
WO2004032864A2 (en) 2002-10-07 2004-04-22 Radiorx, Inc. X-nitro compounds, pharmaceutical compositions thereof and uses therof
US6870061B2 (en) 2003-01-10 2005-03-22 Alliant Techsystems Inc. Continuous process and system for production of glycidyl nitrate from glycerin, nitric acid and caustic and conversion of glycidyl nitrate to poly(glycidyl nitrate)
EP1603933A2 (en) 2003-03-13 2005-12-14 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
CN100393698C (zh) 2003-06-25 2008-06-11 第一药品(株) 三环衍生物或其药学上可接受的盐、其制备以及包含它们的药物组合物
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
JP5564158B2 (ja) 2003-07-09 2014-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 亜硝酸塩によって特定の心臓血管状態を処置する方法
GB0326047D0 (en) 2003-11-07 2003-12-10 Univ Sheffield Substance
RU2265440C2 (ru) 2004-01-13 2005-12-10 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ предоперационного лечения рака молочной железы
JP2008512490A (ja) 2004-09-08 2008-04-24 チェルシー・セラピューティクス，インコーポレイテッド 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
US20060264415A1 (en) 2005-04-01 2006-11-23 Methylgene Inc. Inhibitors of histone deacetylase
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US20080255149A1 (en) 2005-09-27 2008-10-16 Novartis Ag Carboxyamine Compounds and Methods of Use Thereof
FR2891843A1 (fr) 2005-10-06 2007-04-13 Erytech Pharma Soc Par Actions Erythrocytes contenant du 5-fluorouracile
CN200946766Y (zh) 2006-06-09 2007-09-12 刘余厚 一种套管式紫外灯
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US8122281B2 (en) 2007-04-13 2012-02-21 International Business Machines Corporation System and method for dependent failure-aware allocation of distributed data-processing systems
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
MX2010011165A (es) 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
EP2128133A1 (en) 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Ezetimibe process and composition
BRPI1006722A2 (pt) 2009-04-09 2017-10-10 Entegrion Inc "método de preparação de hemoderivados desidratado, hemoderivados desidratados, bandagem ou auxílio cirúrgico, método para a preparação de plaquetas sanguíneas fixas desidratadas, plaquetas sanguíneas fixas desidratadas, método para o tratamento de um paciente que sofre de um distúrbio sanguíneo e plaquetas de sangue fixas secas por atomização tendo geometria com cavidades esféricas"
CA2758200A1 (en) 2009-04-10 2010-10-14 Abraxis Bioscience, Llc Nanoparticle formulations and uses thereof
CN101708337B (zh) 2009-08-18 2011-08-10 上海交通大学医学院附属新华医院 一种包载奥沙利铂的人血白蛋白纳米粒的制备方法
RU2411953C1 (ru) 2009-09-02 2011-02-20 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт" Федерального агентства по высокотехнологичной мед. помощи Способ лечения рака молочной железы
US8471041B2 (en) 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
US8530461B2 (en) 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
EP2892537A1 (en) 2012-09-10 2015-07-15 Celgene Corporation Methods for the treatment of locally advanced breast cancer
CA2917403C (en) 2013-08-27 2018-05-29 Halliburton Energy Services, Inc. Energetic cocrystals for treatment of a subterranean formation
US20140220163A1 (en) 2014-02-04 2014-08-07 Hamzeh Soleimani Babadi Powder mixture composition of natural materials for controlling deficiencies in polypeptide alpha and beta hemoglobin chains
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
CN109069420A (zh) 2016-01-11 2018-12-21 埃皮辛特瑞柯斯公司 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法
CN110352190A (zh) 2016-10-14 2019-10-18 埃皮辛特瑞柯斯公司 用于医疗用途的磺氧基烷基有机硝基和相关化合物和药物组合物
US11744859B2 (en) 2017-07-07 2023-09-05 Epicentrx, Inc. Compositions and methods for parenteral administration of therapeutic agents
US20200345689A1 (en) 2018-01-08 2020-11-05 Epicentrx, Inc. METHODS AND COMPOSITIONS UTILIZING RRx-001 FOR RADIOPROTECTION
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
WO2019241276A1 (en) 2018-06-11 2019-12-19 Epicentrx, Inc. Medication infusion devices, systems, and methods
CN115243741A (zh) 2019-12-11 2022-10-25 埃皮辛特瑞柯斯公司 药物输注装置、系统和方法
US20230364112A1 (en) 2020-09-29 2023-11-16 Alps Biotech Co., Ltd. Use of Antcin H and Its Derivatives for Treating Central Nervous System Diseases
CN114621125B (zh) 2020-12-14 2024-07-09 中国科学技术大学 Nlrp3炎症小体抑制剂及其应用
IL309043A (en) 2021-06-09 2024-02-01 Epicentrx Inc Crystalline Abdenase compositions and methods for their preparation and use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370492A (zh) * 2005-08-12 2009-02-18 阿利安特技术系统股份有限公司 环状硝基化合物及其药物组合物和用途
WO2012078992A1 (en) * 2010-12-09 2012-06-14 Radiorx, Inc. Organonitro compounds for use in treating non-hodgkin's lymphoma and leukemia, and methods relating thereto
US20120149678A1 (en) * 2010-12-09 2012-06-14 Oronsky Bryan T Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto
WO2013052803A2 (en) * 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
WO2013052164A1 (en) * 2011-10-07 2013-04-11 Radiorx, Inc. Organonitro thioether compounds and medical uses thereof
US20140308260A1 (en) * 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EPICENTRX, INC.: "RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)", 《HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/NCT02489903?TERM=NCT02489903&DRAW=2&RANK=1》 *
JAN SCICINSKI ET AL: "Preclinical Evaluation of the Metabolism and Disposition of RRx-001, a Novel Investigative Anticancer Agent", 《DRUG METABOLISM AND DISPOSITION》 *
TONY REID ET AL: "Safety and activity of RRx-001 in patients with advanced cancer: a fi rst-in-human, open-label, dose-escalation phase 1 study", 《LANCET ONCOL》 *
WILLIAN L FITCH ET AL: "High resolution MS proves that the development cancer drug, RRx-001,alkylates the hemoglobin beta chain", 《44TH WESTERN REGIONAL MEETING OF THE AMERICAN CHEMICAL SOCIETY》 *
李玲: "《护理综合技能训练》", 31 August 2014, 中国中医药出版社 *

Also Published As

Publication number Publication date
EP3402480A1 (en) 2018-11-21
US20190307723A1 (en) 2019-10-10
EP3402480B1 (en) 2021-03-24
EA201891606A1 (ru) 2019-02-28
US20230233524A1 (en) 2023-07-27
KR20190040931A (ko) 2019-04-19
AU2017207304A1 (en) 2018-07-26
US20260097013A1 (en) 2026-04-09
CA3011103A1 (en) 2017-07-20
IL260515B1 (en) 2026-03-01
ES2880482T3 (es) 2021-11-24
WO2017123593A1 (en) 2017-07-20
DK3402480T3 (da) 2021-06-28
BR112018014027A2 (en) 2018-12-11
MX2018008528A (es) 2019-05-16
CN118236371A (zh) 2024-06-25
JP2019505585A (ja) 2019-02-28
PL3402480T4 (pl) 2021-11-22
AU2017207304B2 (en) 2022-05-26
EP3402480A4 (en) 2019-09-18
US11576895B2 (en) 2023-02-14
PL3402480T3 (pl) 2021-11-22
JP6931004B2 (ja) 2021-09-01
SG11201805942UA (en) 2018-08-30
US12357607B2 (en) 2025-07-15
IL260515A (https=) 2018-09-20

Similar Documents

Publication Publication Date Title
CN109069420A (zh) 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法
ES2705016T3 (es) Derivado de rapamicina para el tratamiento de cáncer de pulmón
ES2717911T3 (es) Combinaciones farmacéuticas que comprenden un inhibidor de B-Raf, un inhibidor de EGFR y opcionalmente un inhibidor de PI3K-alfa
BRPI0609957A2 (pt) uso de malato de sunitinib na preparação de um medicamento para o tratamento de cáncer
RU2414936C1 (ru) Способ лечения рака прямой кишки
JP5049139B2 (ja) 内臓痛を治療するためのオキシコドンの使用
Cohen et al. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer
WO2020236668A1 (en) Leukadherin-1 alone or in combination for use in the treatment of cancer
BR112021014342A2 (pt) Uso de um antagonista mglur5 para tratar tolerância a analgésico opioide
TW201249435A (en) Antitumoral combination comprising cabazitaxel and cisplatin
TW202504617A (zh) 治療對卡介苗療法無反應的高風險非肌肉侵襲性膀胱癌之方法
Jeremiah et al. Vancomycin dosing nomogram for haemodialysis patients.
TW201932119A (zh) 膽道癌用抗腫瘤劑和膽道癌的處理方法
BR112019027889A2 (pt) método de tratamento e formas de dosagem do mesmo
TW201202232A (en) Treatment of GIST with masitinib
JP6823055B2 (ja) 軟髄膜癌腫症の治療方法
JP2014506904A (ja) γセクレターゼ阻害剤の投与方法
TW202532086A (zh) 治療對卡介苗療法無反應之高風險非肌肉侵襲性膀胱癌之方法
US20250049802A1 (en) Combination therapies and uses for treating cancer
Rahman Kawakibi et al. CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA
Johnson Sleep-Related Painful Erections and Stuttering Priapism
WO2026092748A1 (zh) 雄性激素合成抑制剂与parp抑制剂联合用于治疗前列腺癌
TW202416992A (zh) 雌激素受體降解劑之給藥方案
CN118019537A (zh) Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途
TW201420102A (zh) 組合療法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20181221

RJ01 Rejection of invention patent application after publication